Skip to main content

MoneyWorks4Me

Lupin’s commercial partner launches Ranluspec in Europe

12 Nov 2026 Evaluate

Lupin’s commercial partner -- Sandoz has launched Ranluspec, Lupin’s biosimilar Ranibizumab, across Europe, excluding Germany. The launch follows the European Commission approval of Ranluspec in vial and pre-filled syringe presentations and marks an important step in expanding access to high-quality biologic treatment options for retinal diseases.

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A. The indications of Ranluspec encompass the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularization. The launch of Ranluspec in Europe advances Lupin’s strategy of bringing high-quality biosimilars to more patients suffering from retinal and choroidal vascular diseases.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Peers
Company Name CMP
Sun Pharma. Inds. 1901.00
Dr. Reddys Labs. 1388.25
Cipla 1414.75
Lupin 1987.00
Zydus Lifesciences 1195.90
View more..